{
    "clinical_study": {
        "@rank": "159646", 
        "arm_group": [
            {
                "arm_group_label": "M100", 
                "arm_group_type": "Active Comparator", 
                "description": "heparin free CRRT group"
            }, 
            {
                "arm_group_label": "HF1000", 
                "arm_group_type": "Experimental", 
                "description": "CRRT with nafamostat mesilate anticoagulation group"
            }
        ], 
        "brief_summary": {
            "textblock": "Continuous renal replacement therapy (CRRT) has been considered as an effective modality for\n      renal replacement therapy in hemodynamically unstable patients within intensive care unit\n      (ICU) except for the necessity of anticoagulation. The severity and peculiarities of ICU\n      patients often make it equivocal to use anticoagulation. This is a prospective randomized\n      controlled study to show the difference in filter life span and adverse event between HF1000\n      (nafamostat mesilate) group and M100 (heparin-free) group."
        }, 
        "brief_title": "The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy", 
        "completion_date": {
            "#text": "August 2010", 
            "@type": "Actual"
        }, 
        "condition": "Acute Kidney Injury", 
        "condition_browse": {
            "mesh_term": [
                "Acute Kidney Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients who have at least one of the hemorrhagic tendencies of following conditions\n             and needs CRRT hemodynamically;\n\n               1. Platelet count < 100,000\n\n               2. aPTT > 60 sec\n\n               3. PT-INR > 2.0\n\n               4. active hemorrhage\n\n               5. surgery within 48 hours\n\n               6. cerebral hemorrhage within 3 months or history of major bleeding\n\n               7. septic shock or DIC.\n\n        Exclusion Criteria:\n\n          -  pregnancy, breast feeding, possibility of pregnancy,\n\n          -  allergy to nafamostat mesilate,\n\n          -  other conditions that physician consider unfit for candidate."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01761994", 
            "org_study_id": "4-2007-0220"
        }, 
        "intervention": {
            "arm_group_label": [
                "M100", 
                "HF1000"
            ], 
            "description": "Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.", 
            "intervention_name": "Anticoagulation with nafamostat mesilate", 
            "intervention_type": "Drug", 
            "other_name": "futhan"
        }, 
        "intervention_browse": {
            "mesh_term": "Nafamostat"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "nafamostat mesilate", 
            "heparin", 
            "continuous renal replacement therapy"
        ], 
        "lastchanged_date": "January 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Severance Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Mortality in intensive care unit", 
            "measure": "mortality", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01761994"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "collaborator": {
                "agency": "SK Chemicals Co.,Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}